Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.  This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  The initiation of this Phase I clinical trial triggered a $10 million milestone payment from GSK.

"With the successful conclusion of the discovery phase of our GSK alliance, we are intensifying and expanding our efforts in our other ongoing programs that are entirely outside the GSK alliance," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists. In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."

About ChemR23/CCX832

The ligand for ChemR23, chemerin, is a widely expressed protein that circulates in human plasma in an inactive state and becomes biologically activated in inflammatory settings. There is building evidence that suggests chemerin may serve as a biological alarm signal that, under conditions of tissue injury, recruits ChemR23-expressing immune cells. Diseases such as psoriasis are also associated with elevated levels of activated chemerin. In preclinical studies, CCX832 has demonstrated the ability to successfully block
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Inc., a leading supplier of label-free technology that accelerates ... the launch of BLItz™, a revolutionary new platform that ... to conduct label-free analyses of proteins using small sample ... new platform was unveiled today at the IBC Antibody ...
... 2011  TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor ... allergies, cold and flu symptoms and migraine headaches, today announced ... The new facility located at 4400 Route 9 ... staff and enable further expansion for the Company,s future growth. ...
Cached Medicine Technology:ForteBio Introduces BLItz™, a Revolutionary, Micro-volume Label-free Analysis Platform for Personal Assays 2ForteBio Introduces BLItz™, a Revolutionary, Micro-volume Label-free Analysis Platform for Personal Assays 3TheraBiogen, Inc. Relocates Corporate Headquarters to New Jersey 2
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... center management, Decatur County Memorial Hospital recently transitioned management companies to partner with ... Center Management for their outpatient wound center. , Transitioning wound care management ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department ... qualified for the position they are applying for, they are unable to pass the ... are considering altering drug testing policies in order to be able to hire long-term, ...
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3
... in The Journal of Sexual Medicine reveals that for ... clitoris was shown to activate three separate and distinct ... claimed that the major source of genital sensation is ... vaginal or cervical stimulation., Researchers led by Barry R. ...
... secret that a high-fat diet isn,t healthy. Now researchers ... that is. Writing in the Journal of ... Professor of Medicine and director of the Institute for ... Medicine at the University of Pennsylvania, and colleagues, describe ...
... HealthDay Reporter , SUNDAY, Sept. 11 (HealthDay News) -- Seven ... Pearl Harbor still packs a psychological punch for many Americans. ... as the moment when a stunned young country shed a ... with the now-iconic can-do bravado of the "Greatest Generation." ...
... 2011 -- Researchers at the Hebrew University of Jerusalem ... insulin-producing beta cells in the pancreas -- a breakthrough ... restore or increase beta cell function in people with ... multi-year project was led by Prof. Yuval Dor of ...
... waste being dumped where it could poison people and ... be one solution, says Panate Manomaivibool of the International ... Sweden, in a new thesis. In recent years, ... in China, India and various African countries have been ...
... gastrointestinal (GI) bleeding needs to be considered when ... aspirin for cardiovascular disease and cancer. According to ... Hepatology , the use of low-dose aspirin increases ... being increased further with accompanying use of cardiovascular ...
Cached Medicine News:Health News:Stimulation of female genital regions produces strong activation of various brain sites 2Health News:High-fat diet and lack of enzyme can lead to heart disease in mice 2Health News:9/11 Left Permanent Scars on the American Psyche 2Health News:9/11 Left Permanent Scars on the American Psyche 3Health News:9/11 Left Permanent Scars on the American Psyche 4Health News:9/11 Left Permanent Scars on the American Psyche 5Health News:9/11 Left Permanent Scars on the American Psyche 6Health News:Key signal that prompts production of insulin-producing beta cells points way toward diabetes cure 2Health News:Producer responsibility solution to electronic waste in developing countries 2Health News:Producer responsibility solution to electronic waste in developing countries 3Health News:Even low-dose aspirin may increase risk of GI bleeding 2
Provides a combination of concentrated cold / hot and compression for the knee...
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery....
Provides a combination of concentrated cold / hot and compression for the back...
Provides compression, support, immobilization for the knee in addition to cold / hot therapy...
Medicine Products: